# 2021 Mantle Cell Lymphoma Scientific Workshop

April 6-8, 2021  
Draft Agenda | Virtual Event

**NOTE: All agenda times are Eastern U.S. Other common time zones in red.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Time Zone</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:15am</td>
<td>Welcome and Introductions <em>(7am PST, 9am CST, 4pm CET)</em></td>
<td>Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation, Martin Dreyling, MD, PhD, Chair, LRF MCL Consortium Executive Committee</td>
</tr>
<tr>
<td>10:15 - 11:15am</td>
<td>Keynote Address</td>
<td>Elaine S. Jaffe, MD, National Cancer Institute</td>
</tr>
<tr>
<td>11:15 - 11:20am</td>
<td>Stretch Break</td>
<td></td>
</tr>
<tr>
<td>11:20 – 12:35pm</td>
<td>Mantle Cell Lymphoma (MCL) Biology I <em>(8:20am PST, 10:20am CST, 5:20pm CET)</em></td>
<td>moderator: Leticia Quintanilla-Fend, MD, University of Tuebingen</td>
</tr>
<tr>
<td></td>
<td><strong>E3 Ligase UBR5 HECT domain mutations in lymphoma control maturation of B cells via aberrant splicing</strong></td>
<td>Shannon Buckley, PhD, University of Nebraska Medical Center</td>
</tr>
<tr>
<td></td>
<td><strong>Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma</strong></td>
<td>Elias Campo, MD PhD, Hospital Clinic Barcelona – IDIBAPS</td>
</tr>
<tr>
<td></td>
<td><strong>Long-read sequencing reveals a complex CCDN1 rearrangement and haplotype-specific methylation in a case of non-nodal leukemic MCL</strong></td>
<td>Johannes Hellmuth, MD, University Hospital LMU Munich</td>
</tr>
<tr>
<td></td>
<td><strong>Cyclin D1 activates a transcriptional program relevant for mantle cell lymphoma pathogenesis</strong></td>
<td>Pedro Jares, PhD, Hospital Clinic Barcelona – IDIBAPS</td>
</tr>
<tr>
<td>12:35-1:05pm</td>
<td>30 min Lunch Break</td>
<td></td>
</tr>
<tr>
<td>1:05 – 2:20pm</td>
<td>MCL Biology II <em>(10:05am PST, 12:05pm CST, 7pm CET)</em></td>
<td>moderator TBA</td>
</tr>
<tr>
<td></td>
<td><strong>Metabolomic and Fluxomic Study of Mantle Cell Lymphoma Bionetwork: Metabolic Insights as Guidance to Detect and Overcome BTKi Resistance</strong></td>
<td>Metabolomic and Fluxomic Study of Mantle Cell Lymphoma Bionetwork: Metabolic Insights as Guidance to Detect and Overcome BTKi Resistance</td>
</tr>
</tbody>
</table>
Alexander Shestov, PhD, University of Pennsylvania

The role of CEACAM1 in BCR signaling and immunotherapy in mantle cell lymphoma
Vu Ngo, PhD, City of Hope

Dynamic Changes in Gene Mutational Landscape with Preservation Of Core Mutations in Mantle Cell Lymphoma
Mariusz Wasik, MD, Fox Chase Cancer Center

Cannabinoids reduce malignant B-cells and affect non-malignant leukocytes in the blood of patients with indolent B cell leukemia
Birgitta Sander, MD, PhD, Karolinska Institutet

2:20-2:25pm Stretch Break

2:25-3:50pm MCL Novel Pathways and Targets (11:25am PST, 1:25pm CST, 8:25pm CET)
Moderator: Eduardo M. Sotomayor, MD, George Washington Univ. Cancer Center
Stromal cell signaling reprogramming as a novel vulnerability for combination therapies to overcome immune suppression in mantle cell lymphoma
Fengdong Cheng, MD, The GW University Cancer Center

Chimeric Antigen Receptor T Cells Targeting Clonally Restricted Lambda Light Chain Surface Immunoglobulin Eradicate Mantle Cell Lymphoma
Raghuveer Ranganathan, MD, University of North Carolina, Chapel Hill

Time-resolved scRNA-seq of ibrutinib-treated mantle cell lymphoma cell line reveals the heterogeneous cellular behaviour to drug treatment
Hilka Rauert-Wunderlich, PhD, University of Wuerzburg Institute of Pathology

Targeting Transcriptional Programming Disables and Overcomes the Evolution of Ibrutinib-Resistance in Mantle Cell Lymphoma
Jianguo Tao, MD, PhD, Moffitt Cancer Center

XLA immunophenotype in MCL patients attaining a prolonged complete response to the selective BTK inhibitor, tirabrutinib
Harriet Walter, MD, PhD, University of Leicester

3:50– 4:00 pm Day 1 Wrap Up

Wed, April 7

Novel Targets and Therapies/ Personalization of Therapy (7am PST, 9am CST, 4pm CET)
Moderator: Leo I. Gordon, MD, FACP, Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Molecular Heterogeneity and Tumor-Immune Evolution in Refractory Mantle Cell Lymphoma
Vivian Jiang, PhD MD, Anderson Cancer Center

Class B and class C CpG deoxynucleotide-conjugated gold nanoparticles for treatment of mantle cell lymphoma
Adam Lin, MD, PhD, Northwestern University

Exploiting the epigenetic and mRNA splicing regulator PRMT5, as a novel therapeutic target in mantle cell lymphoma
Yixin Yao, PhD, MD, Anderson Cancer Center

Effects of Proteasome Inhibitors in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-clinical Models
Shalin Kothari, MD, Yale University

11:15-11:20am  Stretch Break

11:20-12:50pm  Minimal Residual Disease in MCL (8:20am PST, 10:20am CST, 5:20pm CET)
Moderator: Martin Dreyling, MD, PhD, University Hospital LMU Munich

Comparative analysis of standardized IG-based ASO qPCR, ddPCR and amplicon NGS for MRD monitoring in Mantle cell lymphoma
Christiane Pott, MD, University Hospital Schleswig-Holstein

Utility of NGS-based MRD Assessments in a Frontline Lenalidomide-based Chemoimmunotherapy Treatment Approach
Zachary Epstein-Peterson, MD, Memorial Sloan Kettering Cancer Center

Ibrutinib Maintenance (I-M) in Mantle Cell Lymphoma (MCL) Following Frontline Intensive Induction: Interim Response, Sequential MRD and Safety Evaluation
Reem Karmali, MD, Northwestern University

Assays for Circulating Tumor DNA Predict Survival and Often Precede Clinical Relapse in Mantle Cell Lymphoma
Rahul Lakhotia, MD, National Heart, Lung, and Blood Institute

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)
Mitchell Smith, MD, PhD, George Washington University Cancer Center

Roundtable Discussion: MRD in MCL

12:50-1:20pm  30 min Lunch Break

1:20-2:45pm  MCL Therapeutic Resistance/ Prognostic and Predictive Biomarkers/
Epidemiology and Outcomes (10:20am PST, 12:20pm CST, 7:20pm CET)
Moderator: Peter Martin, MD, Weill Cornell Medicine

Update on SOX11 inhibitors for MCL
Samir Parekh, MD, Icahn School of Medicine at Mount Sinai

Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes
Yucai Wang, MD, PhD, Mayo Clinic, Rochester

A modified scoring system exhibits high efficacy in predicting the prognosis of patients with mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium of 23 Institutions
Chengfeng Bi, MD, PhD, University of Nebraska Medical Center

Molecular Profiling and Preclinical Drug Efficacy to Interrogate Dysregulated Pathways for Precision Medicine in Mantle Cell Lymphoma
Yang Liu, PhD, MD, Anderson Cancer Center

2:45-2:55pm Day Two Wrap Up

2:55-3:15pm MCL Leadership Award | Dr. Michael Williams

3:15-5:15pm 2021 Spring SAB Meeting (LRF Scientific Advisory Board members only)
(12:15pm PST, 2:15pm CST)

Thurs, April 8

10:00-11:30 am Clinical Trials in MCL I (7am PST, 9am CST, 4pm CET)
Moderator: Michael Williams, MD, MSc, University of Virginia Cancer Center

R-MACLO-IVAM is an effective regimen to induce long term remission in untreated mantle cell lymphoma (MCL)
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, University of Miami

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)
Martin Dreyling, MD, PhD, University Hospital LMU Munich

A pilot study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab (R-ABC) for untreated mantle cell lymphoma
Daniel Guy, MD, Washington University in St. Louis
Frontline treatment with ibrutinib with rituximab (IR) combination is highly effective in elderly (≥65 years) patients with mantle cell lymphoma (MCL) – results from a phase II trial
Preetesh Jain, MD, PhD, MD Anderson Cancer Center

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results of the Phase 2 ZUMA-2 Study
Michael Wang, MD MD Anderson Cancer Center

11:30-11:25 am  Stretch Break

11:35 -12:35pm  Clinical Trials in MCL II (8:20am PST, 10:20pm CST, 5:20pm CET)
Moderator: Martin Dreyling, MD, PhD, University Hospital LMU Munich

NCTN Update in MCL: Current and Planned Studies
Brad Kahl, MD, Washington University School of Medicine

European MCL Network: Current Study Generation
Martin Dreyling, MD, PhD, University Hospital LMU Munich

12:35 – 1:05pm  30 min Lunch Break

1:05-2:05 pm  COVID-19 and Mantle Cell Lymphoma
Update from LRF COVID Vaccine and Lymphoma Panel
Speaker TBA

COVID-19 in Patients Receiving CD20-Depleting Immunochemotherapy for B-Cell Lymphoma
Oliver Weigert, MD, University Hospital LMU Munich

2:05-2:50pm  Collaborative Discussion: Upcoming MCL Clinical Trials
Moderator: Martin Dreyling, MD, PhD, University Hospital LMU Munich
Attendees will be invited to give a brief overview of any upcoming clinical trials and requests for collaboration as part of an open mic discussion.

2:50-3:00 pm  Michael Williams MD Abstract Award Winners Announced

3:00-3:30pm  MCL Workshop Concluding Remarks (12:05pm PST, 2:05pm CST, 9:05pm CET)
Martin Dreyling, MD, PhD, MCL Consortium Executive Committee Chair
University Hospital LMU Munich